videobanner
Race Against Time To Protect Life Safety

Achieve full-process on-site detection within 30 minutes

Announcement

The company’s English name has changed from “Jiangsu Qitian Gene Biotechnology Co., Ltd.” to “QT Biotech Co., Ltd.”

The Pacesetter In On-site Molecular Detection

Our vision is to be the pacesetter in on-site molecular detection, and to lead the development of the industry through superior R&D strength and innovation ability and make contributions to the protection of human life and safety

RAA Full-Industrial Chain Supplier

Enzyme raw material platform, reagent platform, and instrument platform

scroll down

Cutting-Edge Technology 

Recombinase Aided Amplification Technology

Recombinase Aided Amplification (RAA) technology uses recombinase, single-stranded binding protein, and DNA polymerase under isothermal conditions (37–42℃) to amplify nucleic acids.
RAA overcomes the limitations of traditional PCR that relies on thermal cycling, offering advantages such as isothermal amplification, superior efficiency, high sensitivity and specificity, and user-friendly operation.
RAA aids QT BIO in developing a “more accurate, faster, and more convenient” biosecurity prevention and control system, in advancing molecular detection technologies, in building a comprehensive industry chain for biological prevention and control products, and in leading the upgrade of nucleic acid amplification technology towards “on-site detection and deskilling”.

VIEW MORE
video

Core Platform

Qitian

Raw Material

M-MLV Reverse Transcriptase & RAA/RT-RAA Enzyme Freeze-Dried Pellet (Fluorescent Method)

 

VIEW MORE →
Qitian

Raw Material

Qitian

Reagent

Reagents include extraction reagents, research reagents and detection reagents

VIEW MORE →
Qitian

Reagent

Huadong

Instrument

Based on RAA technology, the instrument features rapid isothermal amplification, compact and portable design, smart analysis, and easy operation.

VIEW MORE →
Qitian

Instrument

Application Field

News

The original company name, “Jiangsu Qitian Gene Biotechnology Co., Ltd.” is nowofficially changed to “QT Biotech Co., Ltd.”, with the abbreviation “QT BIO”. Thetransition period for this name change will commence on December 1, 2024, andconclude on December 31, 2024, During this period, we will gradually carry out thename change process, including but not limited to company logos, promotionalmaterials and contract documents.

2025-10-29

Literature Sharing: Rapid detection of Ebolavirus using isothermal recombinase-aided amplification

In September of this year, the WHO received an alert from the Ministry of Health of the Democratic Republic of the Congo regarding suspected cases of Ebola Virus Disease (EVD). EVD is a highly fatal infectious disease. Although vaccines have become available, rapid case identification remains crucial for outbreak control, creating a persistent and urgent need for rapid diagnostic methods. Notably, as early as 2024, researchers had already developed an effective solution. The literature shared today introduces a diagnostic method suitable for field detection utilizing Recombinase-Aided Amplification (RAA) technology, which can deliver results within 15 minutes.

2025-10-17

Tier-1 Virus, Tier-1 Solution — QT BIO's Detection Kit for Nipah Virus

The Korea Disease Control and Prevention Agency has announced that starting from September 8, Nipah virus infection will be classified as a Level 1 infectious disease. South Korea has implemented a four-tier classification system for infectious diseases since 2020, with Level 1 being the highest. This is the first time a new disease has been added to the Level 1 category since the four-tier system was introduced in 2020. According to South Korea’s infectious disease classification guidelines, suspected and confirmed cases of Nipah virus will undergo public health management measures, including mandatory reporting, isolation, contact tracing, and epidemiological investigations. The World Health Organization has listed Nipah virus in its priority pathogen list, which includes pathogens with pandemic potential.

2025-09-19

Literature Sharing: Rapid and sensitive Cas13a/Cas12a-based one-pot dual-target strategy to detect monkeypox virus and its co-infected viruses

On September 19, 2025, it was reported that the World Health Organization (WHO) had updated its global situation report on the mpox outbreak. Data showed that as of August 31, 2025, a total of 92 countries had reported 38,671 confirmed cases of mpox and 163 deaths, with the majority concentrated in Africa. A collaborative team led by Professor Dan Du from the School of Medicine, Xiamen University and Professor Youzhi Tang from the College of Veterinary Medicine, South China Agricultural University published a paper in Science Bulletin. Based on the trans-cleavage characteristics of Cas13a and Cas12a enzymes in the CRISPR system, this research established one-pot single-target detection methods by combining them with isothermal amplification RAA technology, respectively. Furthermore, these two systems were integrated to create a dual-target detection system.

Authoritative Collaboration

China CDC

China CDC

General Administration of Customs of the People's Republic of China

General Administration of Customs of the People's Republic of China

China Animal Health and Epidemiology Center

China Animal Health and Epidemiology Center

Jiangsu Institute of Parasitic Diseases

Jiangsu Institute of Parasitic Diseases

Leipzig University

Leipzig University

Race against Time to Protect Life Safety

Copyright © 2025 QT Biotech Co., Ltd.
苏ICP备2025209101号-1

营业执照